Breakthrough Monthly GLP-1 Data and $3.22 EPS Beat Headline Q4 Earnings (PFE Q4 2025 Earnings Call)

By Dr. Graph | Updated on Apr 11, 2026 | earnings

Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.

Pfizer's fourth-quarter and full-year 2025 results demonstrated exactly what management had promised: a company fundamentally realigning for a new era of growth. While total annual revenues slightly declined due to the final unwinding of COVID-19 product sales, the core business grew a robust 6%. The quarter was defined by massive strategic moves, taking a $4.4 billion non-cash impairment to aggressively prune the pipeline while simultaneously presenting compelling data that positions Pfizer to disrupt the massive obesity market with the industry's first potential once-a-month GLP-1 injection.

A Core Business Firing on All Cylinders

Pfizer delivered full-year 2025 revenues of $62.6 billion, with a fourth-quarter adjusted EPS of $0.66 that safely beat expectations, capping off a full-year adjusted EPS of $3.22. Most impressively, the company’s cohort of recently launched and acquired products delivered $10.2 billion in annual revenues, representing 14% operational growth.

This strong commercial execution allowed Pfizer to return $9.8 billion to shareholders via dividends while absorbing the final dramatic year-over-year operational decline in its COVID-19 franchise (Paxlovid and Comirnaty), which dropped 40% in Q4 alone. Chief Financial Officer Dave Denton noted that the successful integration of its legacy acquisitions, notably Biohaven and Seagen, is heavily boosting core margins, which expanded to 76% for the year. The company aggressively pursued operational efficiency, deploying a massive AI integration across 1,200 GPUs that helped realize the bulk of its targeted $7.2 billion in net cost savings.

Breakthrough Data for Monthly GLP-1 Candidate

The undeniable star of the earnings report was the unveiling of Phase 2b data from the VESPA-3 study of PF-3944, Pfizer’s proprietary ultra-long-acting GLP-1 receptor agonist. The results successfully validated the holy grail of weight loss treatments: transitioning from weekly to monthly subcutaneous injections without sacrificing competitive efficacy or tolerability.

Chief Scientific Officer Dr. Chris Boshoff detailed that patients achieved a placebo-adjusted weight loss of 10% to 12.3% at week 28 on low and medium doses. More crucially, predictive modeling for a planned 9.6-milligram high monthly dose suggests nearly 16% weight loss by week 28, positioning it as highly competitive with current weekly standards of care. Notably, the Phase 2b data showed no signs of an efficacy plateau at 28 weeks and exhibited a favorable gastrointestinal tolerability profile, clearing the runway for 10 Phase 3 studies expected to launch this year targeting potential approval starting in 2028.

Pipeline Pruning and Strategic Deprioritization

In a decisive move to enforce capital discipline ahead of pending loss-of-exclusivities (LOEs) between 2026 and 2028, Pfizer took a massive $4.4 billion non-cash intangible asset impairment charge during the fourth quarter. This resulted in a GAAP net loss of $0.29 per share for Q4.

Management explicitly noted this impairment was driven by an aggressive pipeline rationalization strategy. A prime example highlighted was the deprioritization of dicitamab vedotin in bladder cancer; ironically, this was done because another Pfizer asset—the recently approved PADCEV (acquired via Seagen)—has performed so exceptionally well, commanding expanded indications and increased revenue projections that effectively cannibalized the need for the overlapping program. CEO Albert Bourla reiterated that the company will funnel these R&D savings directly back into its 20 planned pivotal studies for 2026.

Reaffirming 2026 Guidance

Looking ahead, management confidently reaffirmed their 2026 full-year guidance. Pfizer expects total revenues between $59.5 billion and $62.5 billion, with adjusted diluted EPS between $2.80 and $3.00.

This outlook factors in approximately $1.5 billion in revenue compression linked to upcoming generic entries and assumes a stabilized $5 billion contribution from the COVID portfolio. Excluding the COVID and LOE impacts, the core portfolio is projected to grow 4% operationally. Supported by a robust $7 billion in business development capacity and the planned liquidation of its stake in the ViiV HIV joint venture, Pfizer signaled it is well-capitalized to bridge the gap toward its highly anticipated next-generation pipeline launches at the decade's close.

Frequently Asked Questions

How did Pfizer's core non-COVID business perform in 2025?

Excluding COVID-19 products, Pfizer reported solid core operational revenue growth of 6% for the full year, led by a 14% operational surge from its recently launched and acquired product portfolio.

What makes Pfizer's new GLP-1 drug PF-3944 unique?

PF-3944 features a proprietary ultra-long-acting peptide structure that allows it to bind to the GLP-1 receptor while still bound to albumin, creating the industry's first viable once-a-month GLP-1 injection while maintaining highly competitive weight loss efficacy.

Why did Pfizer report a GAAP loss in the fourth quarter?

The company recorded $4.4 billion in non-cash intangible asset impairments due to aggressive strategic reprioritization of its R&D pipeline, allowing them to shift funding exclusively toward their highest-potential clinical assets.

What is Pfizer's financial outlook for 2026?

Pfizer reaffirmed its 2026 guidance, forecasting revenues between $59.5 billion and $62.5 billion and an adjusted diluted EPS of $2.80 to $3.00, expecting solid 4% operational growth in its core portfolio to offset $1.5 billion in expected generic headwinds.